Deregulation of the microRNA miR124a by DNA methylation has been implicated in various malignancies, but no study reported its methylation status in Hodgkin lymphoma (HL). We evaluated the methylation of the three loci encoding for miR124a using methylation-specific PCR in 64 HL patients and 15 reactive lymph nodes obtained from patients with nonmalignant diseases. Results were correlated with clinicopathological parameters. Methylation rates of miR124a-1, miR124a-2, and miR124a-3 in HL were 17, 50, and 28 %, respectively. None of the nontumoral samples showed aberrant hypermethylation in any of the miR tested. In HL cases, we found that miR124a-1 methylation correlates with high-risk International Prognostic Score (IPS) (score >3, p = 0.04) and that miR124a-2 methylation was more frequent in children (82.3 %, p = 0.006) and men (63.9 %, p = 0.01). Methylation of miR124a-3 was associated with advanced Ann-Arbor stages (p = 0.007). The survival analysis showed that methylation of at least one of the miR124a genes was associated with shortened event-free survival in univariate (p = 0.03) and multivariate (p = 0.02) analyses. These results suggest that miR124a methylation is associated with aggressive HL disease and may be an interesting factor for predicting treatment response.
Hodgkin lymphoma MicroRNA Methylation
This is a preview of subscription content, log in to check access.
This work was supported by the “Ministry of Higher Education, Scientific Research and Technology” and the “Ministry of Health” of Tunisia.
Conflicts of interest
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 321–34.Google Scholar
McKinney PA, Alexander FE, Rickett TJ, Williams J, Cartwright RA. A specialist leukaemia/lymphoma registry in the UK. Part 1: incidence and geographical distribution of Hodgkin’s disease. Leukaemia Research Fund Data Collection Study Group. Br J Cancer. 1989;60:942–7.CrossRefPubMedPubMedCentralGoogle Scholar
Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375–82.CrossRefPubMedGoogle Scholar
Silber J, Lim DA, Petritsch C, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008;6:14–31.CrossRefPubMedPubMedCentralGoogle Scholar
Ando T, Yoshida T, Enomoto S, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124:2367–74.CrossRefPubMedGoogle Scholar
Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010;9:167–81.CrossRefPubMedPubMedCentralGoogle Scholar
Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766–76.CrossRefPubMedGoogle Scholar
Ben Gacem R, Ben Abdelkarim O, Ziadi S, Ben Dhiab M, Trimeche M. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 2014;35:4047–56.CrossRefPubMedGoogle Scholar
Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69:4443–53.CrossRefPubMedGoogle Scholar
Roman-Gomez J, Agirre X, Jiménez-Velasco A, et al. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009;27:1316–22.CrossRefPubMedGoogle Scholar
Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67:1424–9.CrossRefPubMedGoogle Scholar
Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54:2248–56.CrossRefPubMedGoogle Scholar
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–6.CrossRefPubMedPubMedCentralGoogle Scholar
Amara K, Trimeche M, Ziadi S, et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer. 2007;121:2693–702.CrossRefPubMedGoogle Scholar
Singal R, Fredinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relation with clinicopathological features of disease. Oncol Rep. 2004;12:631–7.PubMedGoogle Scholar
Patel A, Groopman JD, Umar A. DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann N Y Acad Sci. 2003;983:286–97.CrossRefPubMedGoogle Scholar
Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008;111:2825–32.CrossRefPubMedGoogle Scholar
Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the down-regulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A. 2002;99:10084–9.CrossRefPubMedPubMedCentralGoogle Scholar
Tsai CL, Li HP, Lu YJ, et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH2-terminal kinase signaling. Cancer Res. 2006;66:11668–76.CrossRefPubMedGoogle Scholar